04:25 AM EDT, 10/23/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We adjust our 12-month target price to $125 from $127, valuing shares at 36.8x our 2026 EPS outlook of $3.40 (up from $3.35; 2025 EPS lifted to $3.04 from $2.98), a premium to BSX's five-year average forward P/E based on our expectations for accelerating growth and strengthening margins. Following BSX's Q3 earnings print, we reiterated our Buy recommendation for shares. A beat on EPS and raise to guidance was a solid start to the second half of the year, with growth encouragingly being broad-based. Cardiovascular was a standout during the quarter, growing 22.4% Y/Y. Regionally, BSX gained traction in Asia on approvals throughout Japan for Farapulse, though China was still a challenging area. U.S. markets remained supportive of double-digit growth. We are optimistic on BSX's market and product portfolio positioning and see outperformance relative to peers being achievable.